CHICAGO — At the ASCO Annual Meeting, Jose Pablo Leone, MD, medical oncologist at Dana-Farber Cancer Institute, spoke with HemOnc Today about the findings of the phase 3 EMBRACA trial.
The study demonstrated that patients with HER2-negative, BRCA1 or BRCA2 germline mutated, locally advanced or metastatic breast cancer treated with talazoparib (Talzenna, Pfizer) had better PFS than those treated with the physician’s choice of therapy, according to Leone, and confirm previous data.
“This data provides reassurance to many clinicians and patients in the United States who are considering this treatment option,” he said. “It also provides an insight into a new therapy for patients with germline mutations in BRCA1 or BRCA2, specifically with the use of PARP inhibitors, which is the class of action of this drug, talazoparib, and builds upon the prior knowledge of other drugs in this space as well.” – by Alaina Tedesco
Diab S, et al. Abstract 1044. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.
Disclosure: Leone reports receiving research funding from Eli Lilly and Company and Kazia Therapeutics